Cannabinoid system in the skin - A possible target for future therapies in dermatology

Experimental Dermatology

Volumn 18, Issue 8, 2009, Pages 669-679

  Kupczyk, Piotr ^a   Reich, Adam ^b   Szepietowski, Jacek C ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Cannabinoid receptors; Drug development; Endocannabinoids; Keratinocytes; Skin

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 1 FLUORO 2,4 DINITROBENZENE; 3 (2 IODO 5 NITROBENZOYL) 1 (1 METHYL 2 PIPERIDINYLMETHYL)INDOLE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; JTE 907; PALMIDROL; RIMONABANT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; CHEMICAL STRUCTURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DERMATOLOGY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG TOLERABILITY; EDEMA; ENZYME REGULATION; ENZYME SYNTHESIS; GENE ACTIVATION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; KERATINOCYTE; LIGAND BINDING; NEUROPATHIC PAIN; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PRURITUS; REVIEW; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN INFLAMMATION; SKIN PRURITUS;

ANIMALS; CANNABINOIDS; CHEMISTRY, PHARMACEUTICAL; DERMATOLOGY; DRUG DESIGN; ENDOCANNABINOIDS; HUMANS; IMMUNE SYSTEM; KERATINOCYTES; MODELS, BIOLOGICAL; MODELS, CHEMICAL; SIGNAL TRANSDUCTION; SKIN; SKIN DISEASES;

EID: 70449484707     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/j.1600-0625.2009.00923.x     Document Type: Review

References (123)

1. Onaivi E S, Leonard C M, Ishiguro H. Endocannabinoids and cannabinoid receptor genetics. Prog Neurobiol 2002, 66:307-344.
2. Stander S, Schmelz M, Metze D. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005, 38:177-188.
3. Elphick M R, Egertova M. The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci 2001, 356:381-408.
4. Elmes S J, Jhaveri M D, Smart D. Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Neurosci 2004, 20:2311-2320.
5. Freund T F, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003, 83:1017-1066.
6. Matsuda L A, Lolait S J, Brownstein M J. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
7. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
8. Klein T W, Newton C, Larsen K. The cannabinoid system and immune modulation. J Leukoc Biol 2003, 74:486-496.
9. Klein T W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005, 5:400-411.
10. Nakamura A, Shiomi H. Recent advances in neuropharmacology of cutaneous nociceptors. Jpn J Pharmacol 1999, 79:427-431.
11. Onaivi E S, Chakrabarti A, Chaudhuri G. Cannabinoid receptor genes. Prog Neurobiol 1996, 48:275-305.
12. Breivogel C S, Griffin G, Di M V. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 2001, 60:155-163.
13. Brown A J. Novel cannabinoid receptors. Br J Pharmacol 2007, 152:567-575.
14. Ahluwalia J, Urban L, Bevan S, Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 2003, 17:2611-2618.
15. Costa B, Comelli F, Bettoni I. The endogenous fatty acid amide, palmitoylethanolamide, has anti-allodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPARγ receptors and neurotrophic factors. Pain 2008, 139:541-550.
16. Hoehe M R, Caenazzo L, Martinez M M. Genetic and physical mapping of the human cannabinoid receptor gene to chromosome 6q14-q15. New Biol 1991, 3:880-885.
17. Basavarajappa B S. Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol 2007, 5:81-97.
18. Fride E. The endocannabinoid-CB(1) receptor system in pre- and postnatal life. Eur J Pharmacol 2004, 500:289-297.
19. Ameri A. The effects of cannabinoids on the brain. Prog Neurobiol 1999, 58:315-348.
20. Herkenham M, Lynn A B, Johnson M R. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 1991, 11:563-583.
21. Lynn A B, Herkenham M. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 1994, 268:1612-1623.
22. Matsuda L A. Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 1997, 11:143-166.
23. Shire D, Carillon C, Kaghad M. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 1995, 270:3726-3731.
24. Boulais N, Misery L. The epidermis: a sensory tissue. Eur J Dermatol 2008, 18:119-127.
25. Komorowski J, Stepien H. The role of the endocannabinoid system in the regulation of endocrine function and in the control of energy balance in humans. Postepy Hig Med Dosw 2007, 61:99-105.
26. Munro S, Thomas K L, bu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
27. Buckley N E, Burbridge D, Buranapramest M. Experimental methods to study the role of the peripheral cannabinoid receptor in immune function. Methods Mol Med 2006, 123:19-40.
28. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K. Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res 2007, 1137:161-169.
29. Staton P C, Hatcher J P, Walker D J. The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain. Pain 2008, 139:225-236.
30. Baker D, Pryce G, Davies W L. In silico patent searching reveals a new cannabinoid receptor. Trends Pharmacol Sci 2006, 27:1-4.
31. Caterina M J, Schumacher M A, Tominaga M. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389:816-824.
32. De P L, Bisogno T, Maccarrone M. The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J Biol Chem 2001, 276:12856-12863.
33. Movahed P, Evilevitch V, Andersson T L. Vascular effects of anandamide and N-acylvanillylamines in the human forearm and skin microcirculation. Br J Pharmacol 2005, 146:171-179.
34. Veronesi B, Oortgiesen M. The TRPV1 receptor: target of toxicants and therapeutics. Toxicol Sci 2006, 89:1-3.
35. Patwardhan A M, Jeske N A, Price T J. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A 2006, 103:11393-11398.
36. Hogestatt E D, Zygmunt P M. Cardiovascular pharmacology of anandamide. Prostaglandins Leukot Essent Fatty Acids 2002, 66:343-351.
37. Taddei S. Evolving the concept of regulation of vascular tone in humans. Br J Pharmacol 2005, 146:165-166.
38. Akerman S, Kaube H, Goadsby P J. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol 2004, 142:1354-1360.
39. Kuenzli S, Saurat J H. Peroxisome proliferator-activated receptors as new molecular targets in psoriasis. Curr Drug Targets Inflamm Allergy 2004, 3:205-211.
40. Sun Y, Bennett A. Cannabinoids: a new group of agonists of PPARs. PPAR Res 2007, 2007:23513.
41. Sun Y, Alexander S P, Kendall D A. Cannabinoids and PPARalpha signalling. Biochem Soc Trans 2006, 34:1095-1097.
42. Bouaboula M, Hilairet S, Marchand J. Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation. Eur J Pharmacol 2005, 517:174-181.
43. Glass M, van D A, Blakemore C. Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors. Neuroscience 2004, 123:207-212.
44. Paus R, Schmelz M, Biro T. Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 2006, 116:1174-1186.
45. Childers S R, Deadwyler S A. Role of cyclic AMP in the actions of cannabinoid receptors. Biochem Pharmacol 1996, 52:819-827.
46. Rao G K, Zhang W, Kaminski N E. Cannabinoid receptor-mediated regulation of intracellular calcium by delta(9)-tetrahydrocannabinol in resting T cells. J Leukoc Biol 2004, 75:884-892.
47. Kaplan B L, Springs A E, Kaminski N E. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol 2008, 76:726-737.
48. Srivastava M D, Srivastava B I, Brouhard B. Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 1998, 40:179-185.
49. Gaoni Y, Mechoulam R. The isolation and structure of delta-1-tetrahydrocannabinol and other neutral cannabinoids from hashish. J Am Chem Soc 1971, 93:217-224.
50. Devane W A, Hanus L, Breuer A. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
51. Huang S M, Bisogno T, Trevisani M. An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 2002, 99:8400-8405.
52. Mechoulam R, Ben-Shabat S, Hanus L. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 1995, 50:83-90.
53. Porter A C, Sauer J M, Knierman M D. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 2002, 301:1020-1024.
54. Sugiura T, Kondo S, Sukagawa A. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 1995, 215:89-97.
55. Maccarrone M, Bari M, Lorenzon T. Anandamide uptake by human endothelial cells and its regulation by nitric oxide. J Biol Chem 2000, 275:13484-13492.
56. Devane W A. New dawn of cannabinoid pharmacology. Trends Pharmacol Sci 1994, 15:40-41.
57. Devane W A, Dysarz F A, Johnson M R. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988, 34:605-613.
58. Natarajan V, Schmid P C, Reddy P V. Biosynthesis of N-acylethanolamine phospholipids by dog brain preparations. J Neurochem 1983, 41:1303-12.
59. Natarajan V, Schmid P C, Reddy P V. Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J Neurochem 1984, 42:1613-9.
60. Maccarrone M, Rossi S, Bari M. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat Neurosci 2008, 11:152-159.
61. Maccarrone M. Fatty Acid amide hydrolase: a potential target for next generation therapeutics. Curr Pharm Des 2006, 12:759-772.
62. Cravatt B F, Demarest K, Patricelli M P. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001, 98:9371-9376.
63. Schlosburg J E, Kinsey S G, Lichtman A H. Targeting fatty acid amide hydrolase FAAH) to treat pain and inflammation. AAPS J 2009, 11:39-44.
64. Long J Z, Li W, Booker L. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 2009, 5:37-44.
65. Singh T A, Santha P, Nagy I. Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience 2005, 136:539-548.
66. Maccarrone M, Di R M, Battista N. The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 2003, 278:33896-33903.
67. Casanova M L, Blazquez C, Martinez-Palacio J. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J Clin Invest 2003, 111:43-50.
68. Paradisi A, Pasquariello N, Barcaroli D. Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. J Biol Chem 2008, 283:6005-6012.
69. Wilkinson J D, Williamson E M. Cannabinoids inhibit human keratinocyte proliferation through a non-CB1/CB2 mechanism and have a potential therapeutic value in the treatment of psoriasis. J Dermatol Sci 2007, 45:87-92.
70. Lau R J, Tubergen D G, Barr M. Phytohemagglutinin-induced lymphocyte transformation in humans receiving delta9-tetrahydrocannabinol. Science 1976, 192:805-807.
71. Galiegue S, Mary S, Marchand J. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 1995, 232:54-61.
72. Cabral G A, Dove Pettit D A. Drugs and immunity: cannabinoids and their role in decreased resistance to infectious disease. J Neuroimmunol 1998, 83:116-123.
73. Berdyshev E V, Schmid P C, Dong Z. Stress-induced generation of N-acylethanolamines in mouse epidermal JB6 P+ cells. Biochem J 2000, 346(Pt 2):369-374.
74. Salzet M, Breton C, Bisogno T. Comparative biology of the endocannabinoid system possible role in the immune response. Eur J Biochem 2000, 267:4917-4927.
75. Tang J L, Lancz G, Specter S. Delta-9-tetrahydrocannabinol-(THC)-mediated inhibition of macrophage macromolecular metabolism is antagonized by human serum proteins and by cell surface proteins. Int J Immunopharmacol 1993, 15:665-672.
76. Tang J L, Lancz G, Specter S. Marijuana and immunity: tetrahydrocannabinol-mediated inhibition of growth and phagocytic activity of the murine macrophage cell line, P388D1. Int J Immunopharmacol 1992, 14:253-262.
77. Sipe J C, Arbour N, Gerber A. Reduced endocannabinoid immune modulation by a common cannabinoid 2 (CB2) receptor gene polymorphism: possible risk for autoimmune disorders. J Leukoc Biol 2005, 78:231-238.
78. Berdyshev E V, Boichot E, Germain N. Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 1997, 330:231-240.
79. Berdyshev E, Boichot E, Corbel M. Effects of cannabinoid receptor ligands on LPS-induced pulmonary inflammation in mice. Life Sci 1998, 63:L125-L129.
80. Kishimoto S, Muramatsu M, Gokoh M. Endogenous cannabinoid receptor ligand induces the migration of human natural killer cells. J Biochem 2005, 137:217-223.
81. Costa B, Conti S, Giagnoni G. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br J Pharmacol 2002, 137:413-420.
82. Lombard C, Nagarkatti M, Nagarkatti P. CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents. Clin Immunol 2007, 122:259-270.
83. Lombard C, Nagarkatti M, Nagarkatti P S. Targeting cannabinoid receptors to treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 2005, 29:915-922.
84. Lombard C, McKallip R J, Hylemon P B. Fas Ligand-dependent and -independent mechanisms of toxicity induced by T cell lymphomas in lymphoid organs and in the liver. Clin Immunol 2003, 109:144-153.
85. Ouyang Y, Hwang S G, Han S H. Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol Pharmacol 1998, 53:676-683.
86. Namazi M R. Cannabinoids, loratadine and allopurinol as novel additions to the antipsoriatic ammunition. J Eur Acad Dermatol Venereol 2005, 19:319-322.
87. Karsak M, Gaffal E, Date R. Attenuation of allergic contact dermatitis through the endocannabinoid system. Science 2007, 316:1494-1497.
88. Facci L, Dal T R, Romanello S. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci U S A 1995, 92:3376-3380.
89. Mazzari S, Canella R, Petrelli L. N-(2-hydroxyethyl)hexadecanamide is orally active in reducing edema formation and inflammatory hyperalgesia by down-modulating mast cell activation. Eur J Pharmacol 1996, 300:227-236.
90. Cui Y Y, D'Agostino B, Risse P A. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux. Eur J Pharmacol 2007, 573:206-213.
91. Palazuelos J, Davoust N, Julien B. The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem 2008, 283:13320-13329.
92. Baker D, Jackson S J, Pryce G. Cannabinoid control of neuroinflammation related to multiple sclerosis. Br J Pharmacol 2007, 152:649-654.
93. Oka S, Yanagimoto S, Ikeda S. Evidence for the involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in 12-O-tetradecanoylphorbol-13-acetate-induced acute inflammation in mouse ear. J Biol Chem 2005, 280:18488-18497.
94. Ueda Y, Miyagawa N, Matsui T. Involvement of cannabinoid CB(2) receptor-mediated response and efficacy of cannabinoid CB(2) receptor inverse agonist, JTE-907, in cutaneous inflammation in mice. Eur J Pharmacol 2005, 520:164-171.
95. Jonsson K O, Persson E, Fowler C J. The cannabinoid CB2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of beta-hexosaminidase from skin slices in vitro. Life Sci 2006, 78:598-606.
96. Ständer S, Weisshaar E, Luger T A. Neurophysiological and neurochemical basis of modern pruritus treatment. Exp Dermatol 2008, 17:161-169.
97. Scarampella F, Abramo F, Noli C. Clinical and histological evaluation of an analogue of palmitoylethanolamide, PLR 120 (comicronized Palmidrol INN) in cats with eosinophilic granuloma and eosinophilic plaque: a pilot study. Vet Dermatol 2001, 12:29-39.
98. Schlosburg J E, Boger D L, Cravatt B F, Lichtman A H. Endocannabinoid modulation of scratching response in an acute allergenic model: a ew prospective neural therapeutic target for pruritus. J Pharmacol Exp Ther 2009, 329:314-23.
99. Eberlein B, Eicke C, Reinhardt H W. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008, 22:73-82.
100. Dvorak M, Watkinson A, McGlone F. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003, 52:238-245.
101. Rukwied R, Watkinson A, McGlone F. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003, 102:283-288.
102. Szepietowski J C, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005, 13:97-103.
103. Szepietowski J C, Reich A, Szepietowski T. Emollients with endocannabinoids in the treatment of uremic pruritus: discussion of the therapeutic options. Ther Apher Dial 2005, 9:277-279.
104. Stander S, Reinhardt H W, Luger T A. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Hautarzt 2006, 57:801-807.
105. Johanek L M, Simone D A. Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain 2004, 109:432-442.
106. LaBuda C J, Koblish M, Little P J. Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain. Eur J Pharmacol 2005, 527:172-174.
107. Jaggar S I, Hasnie F S, Sellaturay S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain 1998, 76:189-199.
108. Russo R, LoVerme J, La R G. Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647. Eur J Pharmacol 2007, 566:117-119.
109. Costa B, Trovato A E, Colleoni M. Effect of the cannabinoid CB1 receptor antagonist, SR141716, on nociceptive response and nerve demyelination in rodents with chronic constriction injury of the sciatic nerve. Pain 2005, 116:52-61.
110. Cravatt B F, Lichtman A H. Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system. Curr Opin Chem Biol 2003, 7:469-475.
111. Sagar D R, Kendall D A, Chapman V. Inhibition of fatty acid amide hydrolase produces PPAR-alpha-mediated analgesia in a rat model of inflammatory pain. Br J Pharmacol 2008, 155:1297-1306.
112. Karanian D A, Brown Q B, Makriyannis A. Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci 2005, 25:7813-7820.
113. Jhaveri M D, Richardson D, Chapman V. Endocannabinoid metabolism and uptake: novel targets for neuropathic andinflammatory pain. Br J Pharmacol 2007, 152:624-632.
114. Lichtman A H, Leung D, Shelton C C. Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J Pharmacol Exp Ther 2004, 311:441-448.
115. Munson A E, Harris L S, Friedman M A. Antineoplastic activity of cannabinoids. J Natl Cancer Inst 1975, 55:597-602.
116. Blazquez C, Carracedo A, Barrado L. Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J 2006, 20:2633-2635.
117. Sarfaraz S, Adhami V M, Syed D N. Cannabinoids for cancer treatment: progress and promise. Cancer Res 2008, 68:339-342.
118. Thompson J F, Scolyer R A, Kefford R F. Cutaneous melanoma. Lancet 2005, 365:687-701.
119. Tsao H, Atkins M B, Sober A J. Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012.
120. Chudnovsky Y, Khavari P A, Adams A E. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005, 115:813-824.
121. Bifulco M, Di M V. Targeting the endocannabinoid system in cancer therapy: a call for further research. Nat Med 2002, 8:547-550.
122. Zhang X, Wang J F, Kunos G. Cannabinoid modulation of Kaposi's sarcoma-associated herpesvirus infection and transformation. Cancer Res 2007, 67:7230-7237.
123. Zheng D, Bode A M, Zhao Q. The cannabinoid receptors are required for ultraviolet-induced inflammation and skin cancer development. Cancer Res 2008, 68:3992-3998.